Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human Pluripotent Stem Cells
![Bio-Techne Logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/11/Bio_Techne__Logo-1024x256.jpg)
MINNEAPOLIS, Nov. 17, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells […]